View Item 

Show simple item record

Adherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer
dc.contributor.authorCaram, Megan E. V.
dc.contributor.authorOerline, Mary K.
dc.contributor.authorDusetzina, Stacie
dc.contributor.authorHerrel, Lindsey A.
dc.contributor.authorModi, Parth K.
dc.contributor.authorKaufman, Samuel R.
dc.contributor.authorSkolarus, Ted A.
dc.contributor.authorHollenbeck, Brent K.
dc.contributor.authorShahinian, Vahakn
dc.date.accessioned2020-12-02T14:41:35Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-12-02T14:41:35Z
dc.date.issued2020-12-01
dc.identifier.citationCaram, Megan E. V.; Oerline, Mary K.; Dusetzina, Stacie; Herrel, Lindsey A.; Modi, Parth K.; Kaufman, Samuel R.; Skolarus, Ted A.; Hollenbeck, Brent K.; Shahinian, Vahakn (2020). "Adherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer." Cancer 126(23): 5050-5059.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/163634
dc.publisherWiley Periodicals, Inc.
dc.publisherCenters for Medicare and Medicaid Services
dc.subject.otherhospital referral region (HRR)
dc.subject.otherurologists
dc.subject.otherprostate cancer
dc.subject.otherout‐of‐pocket cost
dc.subject.othermedication adherence
dc.titleAdherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163634/3/cncr33176.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163634/2/cncr33176-sup-0001-FigS1.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163634/1/cncr33176_am.pdfen_US
dc.identifier.doi10.1002/cncr.33176
dc.identifier.sourceCancer
dc.identifier.citedreferenceLucas FL, Stukel TA, Morris AM, Siewers AE, Birkmeyer JD. Race and surgical mortality in the United States. Ann Surg. 2006; 243: 281 ‐ 286.
dc.identifier.citedreferenceXie Z, St Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately insured patients in the United States. PLoS One. 2019; 14: e0212117.
dc.identifier.citedreferenceCohen MJ, Shaykevich S, Cawthon C, Kripalani S, Paasche‐Orlow MK, Schnipper JL. Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence. J Hosp Med. 2012; 7: 470 ‐ 475.
dc.identifier.citedreferenceGerber BS, Cho YI, Arozullah AM, Lee SY. Racial differences in medication adherence: a cross‐sectional study of Medicare enrollees. Am J Geriatr Pharmacother. 2010; 8: 136 ‐ 145.
dc.identifier.citedreferenceGaskin DJ, Briesacher BA, Limcangco R, Brigantti BL. Exploring racial and ethnic disparities in prescription drug spending and use among Medicare beneficiaries. Am J Geriatr Pharmacother. 2006; 4: 96 ‐ 111.
dc.identifier.citedreferenceGellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007; 22: 1572 ‐ 1578.
dc.identifier.citedreferenceXu KT, Borders TF. Racial and ethnic disparities in the financial burden of prescription drugs among older Americans. J Health Hum Serv Adm. 2007; 30: 28 ‐ 49.
dc.identifier.citedreferenceCamacho FT, Tan X, Alcala HE, Shah S, Anderson RT, Balkrishnan R. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in Medicare breast cancer survivors. Medicine (Baltimore). 2017; 96: e7147.
dc.identifier.citedreferenceFaris NR, Smeltzer MP, Lu F, et al. Evolution in the surgical care of patients with non–small cell lung cancer in the Mid‐South Quality of Surgical Resection Cohort. Semin Thorac Cardiovasc Surg. 2017; 29: 91 ‐ 101.
dc.identifier.citedreferenceSmeltzer MP, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non–small cell lung cancer after resection with curative intent. JAMA Oncol. 2018; 4: 80 ‐ 87.
dc.identifier.citedreferenceAltice CK, Banegas MP, Tucker‐Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017; 109: djw205.
dc.identifier.citedreferenceCenters for Medicare and Medicaid Services. The Centers for Medicare and Medicaid Services Guidance to States on the Low‐Income Subsidy. Centers for Medicare and Medicaid Services; 2009. https://www.cms.gov/Medicare/Eligibility-and-Enrollment/LowIncSubMedicarePresCov/downloads/StateLISGuidance021009.pdf
dc.identifier.citedreferenceSocial Security Administration. Program Operations Manual System: HI 03001.005 Medicare Part D Extra Help (Low‐Income Subsidy or LIS). Published 2019. Accessed August 13, 2020. https://secure.ssa.gov/poms.nsf/lnx/0603001005
dc.identifier.citedreferenceChou YT, Farley JF, Stinchcombe TE, Proctor AE, Lafata JE, Dusetzina SB. The association between Medicare low‐income subsidy and anticancer treatment uptake in advanced lung cancer. J Natl Cancer Inst. 2020; 112: 637 ‐ 646.
dc.identifier.citedreferenceWhite C, Taychakhoonavudh S, Parikh R, Franzini L. Roles of prices, poverty, and health in Medicare and private spending in Texas. Am J Manag Care. 2015; 21: e303 ‐ e311.
dc.identifier.citedreferenceWaalen J, Bruning AL, Peters MJ, Blau EM. A telephone‐based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. Am J Manag Care. 2009; 15: e60 ‐ e70.
dc.identifier.citedreferenceDupclay L, Eaddy M, Jackson J, Raju A, Shim A. Real‐world impact of reminder packaging on antihypertensive treatment adherence and persistence [published correction appears in Patient Prefer Adherence. 2012;6:677]. Patient Prefer Adherence. 2012; 6: 499 ‐ 507.
dc.identifier.citedreferenceFarmer A, Hardeman W, Hughes D, et al. An explanatory randomised controlled trial of a nurse‐led, consultation‐based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. BMC Fam Pract. 2012; 13: 30.
dc.identifier.citedreferencePope GC, Kautter J, Ingber MJ, Freeman S, Sekar R, Newhart C. Evaluation of the CMS‐HCC Risk Adjustment Model. Centers for Medicare and Medicaid Services, Medicare Plan Payment Group, Division of Risk Adjustment and Payment Policy; 2011. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/downloads/Evaluation_Risk_Adj_Model_2011.pdf
dc.identifier.citedreferenceHenning‐Smith CE, Hernandez AM, Hardeman RR, Ramirez MR, Kozhimannil KB. Rural counties with majority black or indigenous populations suffer the highest rates of premature death in the US. Health Aff (Millwood). 2019; 38: 2019 ‐ 2026.
dc.identifier.citedreferenceDimick J, Ruhter J, Sarrazin MV, Birkmeyer JD. Black patients more likely than whites to undergo surgery at low‐quality hospitals in segregated regions. Health Aff (Millwood). 2013; 32: 1046 ‐ 1053.
dc.identifier.citedreferenceShankaran V, Leahy T, Steelquist J, et al. Pilot feasibility study of an oncology financial navigation program. J Oncol Pract. 2018; 14: e122 ‐ e129.
dc.identifier.citedreferenceShankaran V, Linden H, Steelquist J, et al. Development of a financial literacy course for patients with newly diagnosed cancer. Am J Manag Care. 2017; 23 ( 3 suppl ): S58 ‐ S64.
dc.identifier.citedreferenceYezefski T, Steelquist J, Watabayashi K, Sherman D, Shankaran V. Impact of trained oncology financial navigators on patient out‐of‐pocket spending. Am J Manag Care. 2018; 24 ( 5 suppl ): S74 ‐ S79.
dc.identifier.citedreferenceLeslie RS. Using arrays to calculate medication utilization. Presented at: SAS Global Forum 2007; April 16‐19, 2007; Orlando, FL.
dc.identifier.citedreferenceLee M, Salloum RG. Racial and ethnic disparities in cost‐related medication non‐adherence among cancer survivors. J Cancer Surviv. 2016; 10: 534 ‐ 544.
dc.identifier.citedreferenceScher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration‐resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34: 1402 ‐ 1418.
dc.identifier.citedreferenceCubanski J, Damico A, Neuman T. Medicare Part D in 2018: The Latest on Enrollment, Premiums, and Cost Sharing. Kaiser Family Foundation; 2018. https://www.kff.org/medicare/issue-brief/medicare-part-d-in-2018-the-latest-on-enrollment-premiums-and-cost-sharing/
dc.identifier.citedreferenceGallups SF, Connolly MC, Bender CM, Rosenzweig MQ. Predictors of adherence and treatment delays among African American women recommended to receive breast cancer chemotherapy. Womens Health Issues. 2018; 28: 553 ‐ 558.
dc.identifier.citedreferenceDavis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first‐line therapy in metastatic prostate cancer. N Engl J Med. 2019; 381: 121 ‐ 131.
dc.identifier.citedreferenceHussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration‐resistant prostate cancer. N Engl J Med. 2018; 378: 2465 ‐ 2474.
dc.identifier.citedreferenceFizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration‐sensitive prostate cancer. N Engl J Med. 2017; 377: 352 ‐ 360.
dc.identifier.citedreferenceCaram MEV, Kaufman SR, Modi PK, et al. Adoption of abiraterone and enzalutamide by urologists. Urology. 2019; 131: 176 ‐ 183.
dc.identifier.citedreferenceDusetzina SB, Keating NL. Mind the gap: why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy. J Clin Oncol. 2016; 34: 375 ‐ 380.
dc.identifier.citedreferenceKnight TG, Deal AM, Dusetzina SB, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J Oncol Pract. 2018; JOP1800120.
dc.identifier.citedreferenceJagsi R, Pottow JA, Griffith KA, et al. Long‐term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population‐based registries. J Clin Oncol. 2014; 32: 1269 ‐ 1276.
dc.identifier.citedreferenceBestvina CM, Zullig LL, Rushing C, et al. Patient‐oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014; 10: 162 ‐ 167.
dc.identifier.citedreferenceZafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out‐of‐pocket expenses and the insured cancer patient’s experience. Oncologist. 2013; 18: 381 ‐ 390.
dc.identifier.citedreferenceFarias AJ, Hansen RN, Zeliadt SB, Ornelas IJ, Li CI, Thompson B. The association between out‐of‐pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. Am J Clin Oncol. 2018; 41: 708 ‐ 715.
dc.identifier.citedreferenceKaisaeng N, Harpe SE, Carroll NV. Out‐of‐pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm. 2014; 20: 669 ‐ 675.
dc.identifier.citedreferenceFarias AJ, Du XL. Association between out‐of‐pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among Medicare patients with breast cancer. J Clin Oncol. 2017; 35: 86 ‐ 95.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33176_am.pdf
Size:
340.2KB
Format:
PDF
View/Open
Name:
cncr33176-sup-0001-FigS1.pdf
Size:
470.0KB
Format:
PDF
View/Open
Name:
cncr33176.pdf
Size:
213.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.